Mercer Global Advisors Inc. ADV Acquires New Shares in Actuate Therapeutics (NASDAQ:ACTU)

Mercer Global Advisors Inc. ADV acquired a new stake in shares of Actuate Therapeutics (NASDAQ:ACTU) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 16,344 shares of the company’s stock, valued at approximately $130,000. Mercer Global Advisors Inc. ADV owned about 0.08% of Actuate Therapeutics at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ACTU. Freestone Capital Holdings LLC purchased a new stake in shares of Actuate Therapeutics during the fourth quarter valued at $80,000. Envestnet Asset Management Inc. purchased a new position in Actuate Therapeutics in the fourth quarter worth about $83,000. Sigma Planning Corp purchased a new position in Actuate Therapeutics in the fourth quarter worth about $128,000. Voss Capital LP purchased a new position in Actuate Therapeutics in the fourth quarter worth about $440,000. Finally, BIOS Capital Management LP purchased a new position in Actuate Therapeutics in the fourth quarter worth about $78,753,000.

Actuate Therapeutics Price Performance

Shares of NASDAQ:ACTU opened at $10.55 on Friday. Actuate Therapeutics has a 52-week low of $5.51 and a 52-week high of $11.73. The stock’s 50-day simple moving average is $8.23 and its two-hundred day simple moving average is $8.28.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.06).

Wall Street Analysts Forecast Growth

ACTU has been the topic of several research reports. HC Wainwright initiated coverage on Actuate Therapeutics in a research report on Monday, March 17th. They issued a “buy” rating and a $20.00 target price on the stock. Craig Hallum initiated coverage on Actuate Therapeutics in a research report on Tuesday, April 22nd. They issued a “buy” rating and a $21.00 target price on the stock.

Actuate Therapeutics Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.